← board
PRPH
distress 8/10 · high distress / dilution risk$0.06-14%today-99% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
-66%
Price & events
-71.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-14.3%
1D
+0.0%
1W
-25.0%
1M
-50.0%
3M
-71.4%
6M
-98.5%
1Y
-99.8%
2Y
-99.9%
5Y
-99.9%
All
Overview
- Market Cap
- $840.96K
- Volume
- 149.40K
- 52 Week Range
- $0.06 – $6.10
- Total Shares
- 14.02M
- Float Shares
- 13.68M
- Short %
- 0.71%
- % Held by Insiders
- 2.37%
- % Held by Institutions
- 0.07%
- RVOL
- 1.49x
- Beta
- 0.07
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 6
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-02-03partnershipCrown Medical Collections update: more than 60% of claims are from commercial payors that partially reimbursed, indicating higher recovery rates.SEC 8-K
- 2026-02-03partnershipInitiated potential sale or strategic partnership process for BE-Smart esophageal cancer test, targeting over 70 acquirers.SEC 8-K
- 2025-12-19partnershipNon-binding LOI for reverse merger with Advanced Biological Laboratories S.ASEC 8-K
- SeptemberreadoutEquivir · Receipt of final trial data for Equivir expected in September 2024.SEC 8-K
- 2024-08-14partnershipBE-Smart Esophageal Cancer Diagnostic Test · Collaboration with Forward Healthcare Consultants for commercialization of BE-Smart test.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-09ProPhase Labs (NASDAQ: PRPH) restates Q1 2026 and discloses going concern risk - Stock Titan
- 2026-07-08ProPhase Labs Inc updates its health portfolio as ProPhase Labs stock trades on Nasdaq - Ad-hoc-news.de
- 2026-07-07ProPhase Labs Inc explores growth opportunities in diagnostics and consumer health - Ad-hoc-news.de
- 2026-07-01ProPhase Labs, Inc. (PRPH) Q1 2026 10-Q: Financials, Stock Info, and Key SEC Filing Details - Minichart
- 2026-06-30ProPhase Labs (PRPH) flags going concern risk after Q1 2026 loss and heavy financing - Stock Titan
- 2026-06-17Prophase Labs Inc (PRPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
- 2026-06-17Prophase Labs Inc (PRPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
- 2026-06-01ProPhase Labs, Inc. FY 2025: Revenue $4.35M, EPS ($1.74) — 10-K Summary - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.